Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
vlag Wave Life Sciences Ltd. 30/04 7,720 USD
+5,18% 		+5,18%
vlag Windtree Therapeutics Inc 30/04 1,170 USD
+3,54% 		+3,54%

Nieuws over “Biotechnologie”

30/04 · REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights · Persbericht

30/04 · REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights · Persbericht

30/04 · 10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference · Persbericht

30/04 · DBV Technologies Reports First Quarter 2025 Financial Results · Persbericht

30/04 · Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025 · Persbericht

30/04 · Combined General Meeting of May 22, 2025 - Availability of the preparatory documents · Persbericht

30/04 · Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director · Persbericht

30/04 · Beursagenda: Belgische bedrijven · Trends (€)

(ABM FN) Hieronder volgen de belangrijkste items op de financiële agenda voor België tot en met donderdag 8 mei 2025:DONDERDAG 1 MEI 202509:00 Euronext Brussel gesloten op Dag van de ArbeidVRIJDAG 2 MEI 202509:00 WDP - Ex-dividend00:00...

30/04 · Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia · Persbericht

30/04 · Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th · Persbericht

30/04 · New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) · Persbericht

30/04 · Dit zit in onze portefeuille (30/04/2025) · Trends (€)

Van 7C Solarparken tot MDxHealth, dit zit deze week in onze portefeuille. The post Dit zit in onze portefeuille (30/04/2025) appeared first on Trends Kanaal Z.

30/04 · Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call · Persbericht

30/04 · Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 · Persbericht

30/04 · Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery · Persbericht

29/04 · GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F · Persbericht

29/04 · Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update · Persbericht

29/04 · Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025 · Persbericht

29/04 · Novavax Appoints Charles Newton to Board of Directors · Persbericht

29/04 · Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy · Persbericht

29/04 · Insmed To Present at the BofA Securities 2025 Health Care Conference · Persbericht

Mijn selecties